Pinkney J H, Goodrick S J, Katz J, Johnson A B, Lightman S L, Coppack S W, Mohamed-Ali V
University of Bristol, Department of Medicine, Bristol Royal Infirmary, UK.
Clin Endocrinol (Oxf). 1998 Nov;49(5):583-8. doi: 10.1046/j.1365-2265.1998.00573.x.
To study interactions between leptin and the pituitary-thyroid axis, both in euthyroid and dysthyroid states.
We investigated the relationships of plasma leptin to levels of free thyroid hormones and TSH in 18 patients with newly diagnosed hyperthyroidism, 22 with newly diagnosed primary hypothyroidism, and 32 lean (body mass index [BMI] < 30) and 37 obese (BMI > 30 kg/m2) euthyroid subjects. Hypothyroid patients were restudied during thyroxine replacement treatment.
Median [interquartile range] plasma leptin concentrations were highest in obese euthyroid subjects (31.5 [19.0-48.0] and in untreated hypothyroid patients (19.2 [11.5-31.5]), and lowest levels in untreated hyperthyroid patients (8.9 [5.5-11.1]) and lean euthyroid control subjects (6.6 [3.9-14.4] micrograms/l (Kruskall-Wallis one-way analysis of variance; P < 0.0001). In euthyroid subjects, plasma leptin levels were higher in obese than in lean subjects (P < 0.00001). In obese subjects plasma levels of TSH correlated with percentage body fat (r = 0.67; P < 0.001) and plasma leptin (r = 0.61; P < 0.001). In untreated hyperthyroid subjects plasma leptin was unrelated to free T3, and in untreated hypothyroidism plasma leptin was unrelated to either free T3 or TSH concentrations (all P = NS). In untreated hyperthyroid, but not hypothyroid, patients plasma leptin concentrations correlated with BMI (r = 0.57; P = 0.02). Treatment of hypothyroidism with thyroxine resulted in a significant reduction in plasma leptin concentrations from 20.8 (11.8 to 31.6) to 12.9 (4.6-21.2) micrograms/l (P = 0.005), but BMI did not change significantly in the hypothyroid subjects being studied prospectively.
(i) In euthyroid subjects, plasma leptin and TSH levels correlate, and both are positively correlated with adiposity. (ii) Plasma leptin was significantly elevated in hypothyroid subjects, to levels similar to those seen in obese euthyroid subjects. (iii) Treatment of hypothyroidism resulted in a reduction in the raised plasma leptin levels. The data are consistent with the hypothesis that leptin and the pituitary-thyroid axis interact in the euthyroid state, and that hypothyroidism reversibly increases leptin concentrations.
研究在甲状腺功能正常和异常状态下瘦素与垂体 - 甲状腺轴之间的相互作用。
我们调查了18例新诊断的甲状腺功能亢进患者、22例新诊断的原发性甲状腺功能减退患者、32例体重正常(体重指数[BMI]<30)和37例肥胖(BMI>30kg/m²)甲状腺功能正常的受试者血浆瘦素水平与游离甲状腺激素及促甲状腺激素(TSH)水平之间的关系。甲状腺功能减退患者在接受甲状腺素替代治疗期间再次接受研究。
肥胖甲状腺功能正常的受试者(31.5[19.0 - 48.0])和未经治疗的甲状腺功能减退患者(19.2[11.5 - 31.5])的血浆瘦素浓度中位数[四分位间距]最高,未经治疗的甲状腺功能亢进患者(8.9[5.5 - 11.1])和体重正常的甲状腺功能正常对照受试者(6.6[3.9 - 14.4]微克/升)的血浆瘦素浓度最低(Kruskal - Wallis单向方差分析;P<0.0001)。在甲状腺功能正常的受试者中,肥胖者的血浆瘦素水平高于体重正常者(P<0.00001)。在肥胖受试者中,血浆TSH水平与体脂百分比(r = 0.67;P<0.001)和血浆瘦素(r = 0.61;P<0.001)相关。在未经治疗的甲状腺功能亢进受试者中,血浆瘦素与游离T3无关,在未经治疗的甲状腺功能减退患者中,血浆瘦素与游离T3或TSH浓度均无关(所有P =无显著性差异)。在未经治疗的甲状腺功能亢进患者而非甲状腺功能减退患者中,血浆瘦素浓度与BMI相关(r = 0.57;P = 0.02)。用甲状腺素治疗甲状腺功能减退导致血浆瘦素浓度从20.8(11.8至31.6)显著降低至12.9(4.6 - 21.2)微克/升(P = 0.005),但在接受前瞻性研究的甲状腺功能减退受试者中BMI无显著变化。
(i)在甲状腺功能正常的受试者中,血浆瘦素和TSH水平相关,且两者均与肥胖呈正相关。(ii)甲状腺功能减退受试者的血浆瘦素显著升高,达到与肥胖甲状腺功能正常受试者相似的水平。(iii)甲状腺功能减退的治疗导致升高的血浆瘦素水平降低。这些数据与瘦素和垂体 - 甲状腺轴在甲状腺功能正常状态下相互作用以及甲状腺功能减退可逆性增加瘦素浓度的假设一致。